Trial Profile
A Phase I/II Trial of Combination Immunotherapy With Nivolumab and a CCR2/CCR5 Dual Antagonist (BMS-813160) With or Without GVAX Following Chemotherapy and Radiotherapy for Locally Advanced Pancreatic Ductal Adenocarcinomas (PDACs)
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Feb 2024
Price :
$35
*
At a glance
- Drugs BMS 813160 (Primary) ; Nivolumab (Primary) ; Tumour cell vaccine-GVAX (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 30 Jan 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.
- 30 Jan 2024 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
- 25 Aug 2023 Planned End Date changed from 1 Dec 2023 to 31 Dec 2023.